A group from Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Karolinska Institutet, Sweden has reported about a new glyca marker, bisecting GlcNAc, which is able to predict cognitive decline in amyloid- and tau-negative patients.
https://academic.oup.com/braincomms/article/6/6/fcae371/7826117?login=false
This is a reprt about an early biomarker for Alzheimer’s disease.
In Alzheimer’s disease, it has been known that an increased accumulation and aggregation of amyloid β-peptide (Aβ) causes amyloid formation in the brain followed by phosphorylation of tau and neurodegeneration and cognitive decline. In this study, it was found that Bisecting GlcNAc could be an early Alzheimer’s disease biomarker, which is able to predict cognitive decline already at an amyloid-/tau-negative stage.
